BibTex format
@article{Maher:2022:10.1186/s12931-022-02095-6,
author = {Maher, TM and Bourdin, A and Volkmann, ER and Vettori, S and Distler, JHW and Alves, M and Stock, C and Distler, O},
doi = {10.1186/s12931-022-02095-6},
journal = {Respiratory Research},
title = {Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects},
url = {http://dx.doi.org/10.1186/s12931-022-02095-6},
volume = {23},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: The forced vital capacity (FVC) of healthy individuals depends on their age, sex, ethnicity and height. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is characterised by loss of FVC. We compared FVC values in the subjects with SSc-ILD in the SENSCIS trial of nintedanib versus placebo with values from hypothetical matched healthy references. METHODS: The SENSCIS trial enrolled subjects with SSc with first non-Raynaud symptom in the prior ≤ 7 years, extent of fibrotic ILD on HRCT ≥ 10%, and FVC ≥ 40% predicted. FVC at baseline and decline in FVC over 52 weeks were compared with FVC values in hypothetical healthy reference subjects matched 1:1 to the subjects in the trial for age, sex, ethnicity and height, determined using equations published by the European Respiratory Society Global Lung Function Initiative. RESULTS: At baseline, mean (SD) FVC was 2460 (737) mL in the nintedanib group (n = 287) compared with 3403 (787) mL in the hypothetical matched healthy references. Mean (SD) FVC was 2544 (817) mL in the placebo group (n = 286) compared with 3516 (887) mL in the hypothetical matched healthy references. Mean (SE) changes in FVC at week 52, i.e., age-related loss of lung function, in the hypothetical healthy references matched to the nintedanib and placebo groups, respectively, were - 26.3 (0.5) mL and - 25.8 (0.5) mL. The difference in the change in FVC at week 52 between the nintedanib group and the hypothetical healthy references was 26.6 mL (95% CI: 1.2, 52.0; p = 0.04). The difference in the change in FVC at week 52 between the placebo group and the hypothetical healthy references was 77.5 mL (95% CI: 51.4, 103.7; p < 0.0001). CONCLUSIONS: Subjects with SSc-ILD in the SENSCIS trial had impaired lung function at baseline and experienced further deterioration over 52 wee
AU - Maher,TM
AU - Bourdin,A
AU - Volkmann,ER
AU - Vettori,S
AU - Distler,JHW
AU - Alves,M
AU - Stock,C
AU - Distler,O
DO - 10.1186/s12931-022-02095-6
PY - 2022///
SN - 1465-9921
TI - Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
T2 - Respiratory Research
UR - http://dx.doi.org/10.1186/s12931-022-02095-6
UR - https://www.ncbi.nlm.nih.gov/pubmed/35790961
VL - 23
ER -